Floatz logo

Bind-014

CRPC

BIND TherapeuticsPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the CRPC cohort.

Asset / SponsorPhaseRating
Seviteronel
Innocrin Pharmaceutical
Phase 2BB
IMIFOPLATIN
Promontory Therapeutics Inc.
Phase 2CCC
pt-112
Promontory Therapeutics Inc.
Phase 2CCC
Trastuzumab Deruxtecan
Washington D.C. Veterans Affairs Medical Center
Phase 2CCC
Jab-8263
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2CCC
otx015
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1C

Same molecule, other indications

Bind-014 is also rated in:

KRAS Positive Patients With Non-small Cell Lung CancerDormant
B
Indicative ·
62 / 100
View asset →
Squamous Cell Non-small Cell Lung CancerDormant
B
Indicative ·
57 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →